S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Zentalis Pharmaceuticals Stock Forecast, Price & News

-5.49 (-7.02%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
507,390 shs
Average Volume
278,880 shs
Market Capitalization
$3.29 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ZNTL News and Ratings via Email

Sign-up to receive the latest news and ratings for Zentalis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Zentalis Pharmaceuticals logo

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidates are the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer; and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, as well as in Phase 1b clinical trial in combination with chemotherapy in patients with advanced ovarian cancer. The company also develops ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.


Zentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Gap Down to $82.05
December 1, 2021 |  americanbankingnews.com
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Posts Earnings Results
November 11, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$8.75 per share


Net Income
$-117.84 million
Pretax Margin




Free Float
Market Cap
$3.29 billion
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.53 out of 5 stars

Medical Sector

113th out of 1,388 stocks

Pharmaceutical Preparations Industry

47th out of 668 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Frequently Asked Questions

Is Zentalis Pharmaceuticals a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zentalis Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Zentalis Pharmaceuticals stock.
View analyst ratings for Zentalis Pharmaceuticals
or view top-rated stocks.

When is Zentalis Pharmaceuticals' next earnings date?

Zentalis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for Zentalis Pharmaceuticals

How were Zentalis Pharmaceuticals' earnings last quarter?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($1.31) by $1.22.
View Zentalis Pharmaceuticals' earnings history

What price target have analysts set for ZNTL?

7 brokerages have issued twelve-month price objectives for Zentalis Pharmaceuticals' stock. Their forecasts range from $75.00 to $120.00. On average, they anticipate Zentalis Pharmaceuticals' share price to reach $90.43 in the next twelve months. This suggests a possible upside of 24.4% from the stock's current price.
View analysts' price targets for Zentalis Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Zentalis Pharmaceuticals' key executives?

Zentalis Pharmaceuticals' management team includes the following people:

What other stocks do shareholders of Zentalis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zentalis Pharmaceuticals investors own include Esperion Therapeutics (ESPR), Zogenix (ZGNX), AbbVie (ABBV), Advanced Micro Devices (AMD), BioMarin Pharmaceutical (BMRN), Bristol-Myers Squibb (BMY), Clovis Oncology (CLVS), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK) and Phillips 66 (PSX).

When did Zentalis Pharmaceuticals IPO?

(ZNTL) raised $131 million in an initial public offering on Friday, April 3rd 2020. The company issued 7,700,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO.

What is Zentalis Pharmaceuticals' stock symbol?

Zentalis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZNTL."

Who are Zentalis Pharmaceuticals' major shareholders?

Zentalis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Matrix Capital Management Company LP (9.65%), BlackRock Inc. (6.12%), Viking Global Investors LP (4.70%), Primecap Management Co. CA (2.96%), Alliancebernstein L.P. (2.19%) and Capital World Investors (1.52%). Company insiders that own Zentalis Pharmaceuticals stock include Alexis Pinto, Anthony Y Sun, Cam Gallagher, David Michael Johnson, Global Investors Lp Viking, Kevin D Bunker, Kevin D Bunker, Kimberly Blackwell and Melissa B Epperly.
View institutional ownership trends for Zentalis Pharmaceuticals

Which institutional investors are selling Zentalis Pharmaceuticals stock?

ZNTL stock was sold by a variety of institutional investors in the last quarter, including Viking Global Investors LP, Affinity Asset Advisors LLC, Citigroup Inc., Integral Health Asset Management LLC, Ensign Peak Advisors Inc, Morgan Stanley, Invesco Ltd., and Primecap Management Co. CA. Company insiders that have sold Zentalis Pharmaceuticals company stock in the last year include Alexis Pinto, Anthony Y Sun, Cam Gallagher, David Michael Johnson, Kevin D Bunker, Kimberly Blackwell, and Melissa B Epperly.
View insider buying and selling activity for Zentalis Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Zentalis Pharmaceuticals stock?

ZNTL stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Matrix Capital Management Company LP, Geode Capital Management LLC, Goldman Sachs Group Inc., Two Sigma Advisers LP, Wellington Management Group LLP, Alliancebernstein L.P., and Bank of New York Mellon Corp. Company insiders that have bought Zentalis Pharmaceuticals stock in the last two years include Anthony Y Sun, David Michael Johnson, Global Investors Lp Viking, Kevin D Bunker, and Melissa B Epperly.
View insider buying and selling activity for Zentalis Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Zentalis Pharmaceuticals?

Shares of ZNTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zentalis Pharmaceuticals' stock price today?

One share of ZNTL stock can currently be purchased for approximately $72.70.

How much money does Zentalis Pharmaceuticals make?

Zentalis Pharmaceuticals has a market capitalization of $3.29 billion. The company earns $-117.84 million in net income (profit) each year or ($3.68) on an earnings per share basis.

How many employees does Zentalis Pharmaceuticals have?

Zentalis Pharmaceuticals employs 124 workers across the globe.

What is Zentalis Pharmaceuticals' official website?

The official website for Zentalis Pharmaceuticals is www.zentalis.com.

Where are Zentalis Pharmaceuticals' headquarters?

Zentalis Pharmaceuticals is headquartered at 530 SEVENTH AVENUE SUITE 2201, NEW YORK NY, 10018.

How can I contact Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals' mailing address is 530 SEVENTH AVENUE SUITE 2201, NEW YORK NY, 10018. The company can be reached via email at [email protected].

This page was last updated on 12/4/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.